公开(公告)号：EP3331992A1

公开(公告)日：2018-06-13

申请号：EP16750488.5

申请日：2016-08-05

Applicant: Cell Therapy Limited

Inventor： REGINALD, Ajan ,  SULTAN, Sabena ,  EVANS, Martin John

IPC: C12N5/0775

CPC classification number: C12N5/0663 ,  C12N2500/02 ,  C12N2500/05 ,  C12N2500/32 ,  C12N2500/40 ,  C12N2500/84 ,  C12N2500/90

Abstract: The invention relates to immuno-oncology mesodermal progenitor (ioMP) cells and their use in therapy.

公开(公告)号：EP3262158A1

公开(公告)日：2018-01-03

申请号：EP16755992.1

申请日：2016-02-25

Applicant: Agency for Science, Technology and Research

Inventor： NG, Shyh Chang

IPC: C12N5/077

CPC classification number: C12N5/0658 ,  C12N2500/40 ,  C12N2501/115 ,  C12N2501/415 ,  C12N2501/42 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/45

Abstract: The present disclosure describes compositions for preparing a myofiber or myotube from a skeletal muscle stem cell or progenitor cell comprising a carnitine and/or a derivative thereof, a fatty acid a steroid and combinations thereof. Preferred embodiment comprises of 0.1 mM L-carnitine, 0.2 mM 9-cis-linoleic acid and 10 mM dihydrotestosterone. Also disclosed is a composition for inducing expansion of skeletal muscle stem cells or progenitor cells comprising a fibroblast growth factor agonist, a Notch signalling agonist, a nucleic acid, and combinations thereof. Preferred embodiment comprises 20 ng/ml basic fibroblast growth factor (bFGF), 50 μg/ml Delta-like ligand 1 (DLL1), 10 mM hypoxanthine and 1.6 mM thymidine.

公开(公告)号：EP3191837A1

公开(公告)日：2017-07-19

申请号：EP15760182.4

申请日：2015-09-08

Applicant: Ecole Polytechnique Fédérale de Lausanne (EPFL)

Inventor： VANNINI, Nicola ,  LUTOLF, Matthias ,  AUWERX, Johan ,  NAVEIRAS, Olaia ,  GIROTRA, Mukul

IPC: G01N33/50 ,  C12N5/00 ,  A61K31/06 ,  A61K31/277 ,  A61K31/405 ,  A61K31/455 ,  A61K31/496

CPC classification number: A61K31/706 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/198 ,  A61K31/277 ,  A61K31/405 ,  A61K31/44 ,  A61K31/455 ,  A61K31/4965 ,  A61K38/193 ,  A61K45/06 ,  C12N5/0647 ,  C12N2500/40

Abstract: The present invention relates to a specific marker for stem cells having long-term multi-lineage blood reconstitution capability and uses thereof for the preparation of cell composition in view of hematopoietic stem cell medicine and in particular regenerative therapies and bone marrow transplantation. Further, the invention relates to methods and compositions useful in the prevention and/or treatment of decreased blood cell levels and the associated risk of infection.

Abstract translation: 本发明涉及用于具有长期多谱系血液重建能力的干细胞的特异性标记物及其用于从造血干细胞医学特别是再生疗法和骨髓移植来制备细胞组合物的用途。 此外，本发明涉及用于预防和/或治疗血细胞水平降低和感染相关风险的方法和组合物。

公开(公告)号：EP2931914A4

公开(公告)日：2016-08-17

申请号：EP13863551

申请日：2013-12-12

Applicant: MODERNA THERAPEUTICS INC

Inventor： BANCEL STEPHANE ,  DE FOUGEROLLES ANTONIN ,  WHORISKEY SUSAN ,  CHAKRABORTY TIRTHA ,  HUANG ERIC YI-CHUN

IPC: C12P19/34

CPC classification number: C12N5/0602 ,  C07K14/535 ,  C12N9/0069 ,  C12N15/67 ,  C12N2500/40 ,  C12P21/00 ,  C12Y113/12

Abstract: The present invention relates to compositions, methods and kits using cell phenotype altering polynucleotides, cell phenotype altering primary transcripts and cell phenotype altering mmRNA molecules.

公开(公告)号：EP2995948A1

公开(公告)日：2016-03-16

申请号：EP14184110.6

申请日：2014-09-09

Applicant: Ecole Polytechnique Federale de Lausanne (EPFL)

Inventor： Vannini, Nicola ,  Lutolf, Matthias ,  Auwerx, Johan ,  Naveiras, Olaia ,  Girotra, Mukul

IPC: G01N33/50 ,  C12N5/00 ,  A61K31/06 ,  A61K31/277 ,  A61K31/405 ,  A61K31/455 ,  A61K31/496

CPC classification number: A61K31/706 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/198 ,  A61K31/277 ,  A61K31/405 ,  A61K31/44 ,  A61K31/455 ,  A61K31/4965 ,  A61K38/193 ,  A61K45/06 ,  C12N5/0647 ,  C12N2500/40

Abstract: The present invention relates to a specific marker for stem cells having long-term multi-lineage blood reconstitution capability and uses thereof for the preparation of cell composition in view of hematopoietic stem cell medicine and in particular regenerative therapies and bone marrow transplantation. Further, the invention relates to methods and compositions useful in the prevention and/or treatment of decreased blood cell levels and the associated risk of infection.

Abstract translation: 本发明涉及具有长期多谱系血液重建能力的干细胞的特异性标记物，以及用于制造造血干细胞药物，特别是再生疗法和骨髓移植的细胞组合物的用途。 此外，本发明涉及可用于预防和/或治疗降低的血细胞水平和相关的感染风险的方法和组合物。

公开(公告)号：EP2519501B1

公开(公告)日：2015-04-22

申请号：EP10803206.1

申请日：2010-12-28

Applicant: Technische Universität Wien

Inventor： MIHOVILOVIC, Marko ,  SCHNUERCH, Michael ,  KOLEY, Moumita ,  HILBER, Karlheinz ,  KOENIG, Xaver

IPC: C07D213/74 ,  C07D239/48 ,  A61K31/44 ,  A61K31/505 ,  A61P9/00 ,  C12N5/00

CPC classification number: C07D239/48 ,  C07D213/74 ,  C12N5/0657 ,  C12N2500/40

公开(公告)号：EP2788474A1

公开(公告)日：2014-10-15

申请号：EP13814106.4

申请日：2013-12-18

Applicant: Immunicum AB

Inventor： KARLSSON-PARRA, Alex ,  ANDERSSON, Bengt

IPC: C12N5/0784 ,  C12N5/0786

CPC classification number: C12N5/0639 ,  A61K35/15 ,  C12N2500/40 ,  C12N2501/22 ,  C12N2501/2304 ,  C12N2501/24 ,  C12N2506/115

Abstract: Disclosed is a method of producing pro-inflammatory dendritic cells (DCs) originating from at two different, allogeneic donors. In the method, a mixture of allogeneic leukocytes, which allogeneic leukocytes have been obtained from at least two different, allogeneic donors is provided. Subsequently, allogeneic monocytes are isolated from the mixture of allogeneic leukocytes. Thereafter, non-exhausted immature DCs are generated from said isolated allogeneic monocytes, which subsequently are activated to obtain pro-inflammatory DCs.

公开(公告)号：EP2689007A4

公开(公告)日：2014-09-03

申请号：EP12761150

申请日：2012-03-23

Applicant: WHITEHEAD BIOMEDICAL INST ,  BRIGHAM & WOMENS HOSPITAL

Inventor： INCE TAN A

IPC: C12N5/071 ,  C12N5/09 ,  G01N33/50

CPC classification number: C12N5/0018 ,  C12N5/0682 ,  C12N5/0693 ,  C12N2500/14 ,  C12N2500/16 ,  C12N2500/20 ,  C12N2500/22 ,  C12N2500/25 ,  C12N2500/32 ,  C12N2500/34 ,  C12N2500/36 ,  C12N2500/38 ,  C12N2500/40 ,  C12N2500/46 ,  C12N2500/50 ,  C12N2501/01 ,  C12N2501/11 ,  C12N2501/39 ,  C12N2501/395 ,  G01N33/5008 ,  G01N33/5011

公开(公告)号：EP2001998B1

公开(公告)日：2013-07-24

申请号：EP07751073.3

申请日：2007-02-15

Applicant: NEW YORK MEDICAL COLLEGE

Inventor： ANVERSA, Piero

IPC: C12N5/0775

CPC classification number: A61K38/19 ,  A61K35/12 ,  A61K35/34 ,  C12N5/0647 ,  C12N5/0657 ,  C12N5/0662 ,  C12N2500/25 ,  C12N2500/40 ,  C12N2501/105 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/12

Abstract: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration cytokines are disclosed and claimed. Methods and compositions for the development of large arteries and vessels are also disclosed and claimed. The present application also discloses and claims methods and media for the growth, expansion, and activation of human cardiac stem cells.

公开(公告)号：EP2519501A2

公开(公告)日：2012-11-07

申请号：EP10803206.1

申请日：2010-12-28

Applicant: Technische Universität Wien ,  Medizinische Universität Wien

Inventor： MIHOVILOVIC, Marko ,  SCHNUERCH, Michael ,  KOLEY, Moumita ,  HILBER, Karlheinz ,  KOENIG, Xaver

IPC: C07D213/74 ,  C07D239/48 ,  A61K31/44 ,  A61K31/505 ,  A61P9/00 ,  C12N5/00

CPC classification number: C07D239/48 ,  C07D213/74 ,  C12N5/0657 ,  C12N2500/40

Abstract: A process for the production of cardiomocyte-like cells from mammalian cells, comprising cultering mammalian cells in the presence of a compound of formula (I) wherein the radicals have various meanings, compounds of formula (I), wherein the radicals have various meanings and the pharmaceutical use of compounds of formula (I) for the production of cardiomyocyte-like cells from omnipotent, pluripotent or lineage committed mammalian cells and the use of thus produced cardiomyocyte-like cells for treating disorders associated with impaired function of the heart.